Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis

Eric Lawrence Matteson, Frank Buttgereit, Christian Dejaco, Bhaskar Dasgupta

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Diagnosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is based on typical clinical, histologic, and laboratory features. Ultrasonographic imaging in PMR with assessment especially of subdeltoid bursitis can aid in diagnosis and in following response to treatment. In GCA, diagnosis and disease activity are supported with ultrasonographic, MRI, or [18F]fluorodeoxyglucose PET evaluation of large vessels. Glucocorticoids are the primary therapy for PMR and GCA. Methotrexate may be used in patients at high risk for glucocorticoid adverse effects and patients with frequent relapse or needing protracted therapy. Other therapeutic approaches including interleukin 6 antagonists are under evaluation.

Original languageEnglish (US)
Pages (from-to)75-90
Number of pages16
JournalRheumatic Disease Clinics of North America
Volume42
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Polymyalgia Rheumatica
Giant Cell Arteritis
Glucocorticoids
Bursitis
Fluorodeoxyglucose F18
Therapeutics
Methotrexate
Interleukin-6
Recurrence

Keywords

  • Giant cell arteritis
  • Glucocorticoids
  • Polymyalgia rheumatica
  • Treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. / Matteson, Eric Lawrence; Buttgereit, Frank; Dejaco, Christian; Dasgupta, Bhaskar.

In: Rheumatic Disease Clinics of North America, Vol. 42, No. 1, 2016, p. 75-90.

Research output: Contribution to journalArticle

Matteson, Eric Lawrence ; Buttgereit, Frank ; Dejaco, Christian ; Dasgupta, Bhaskar. / Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. In: Rheumatic Disease Clinics of North America. 2016 ; Vol. 42, No. 1. pp. 75-90.
@article{824e97af2d964e3b910f469825232832,
title = "Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis",
abstract = "Diagnosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is based on typical clinical, histologic, and laboratory features. Ultrasonographic imaging in PMR with assessment especially of subdeltoid bursitis can aid in diagnosis and in following response to treatment. In GCA, diagnosis and disease activity are supported with ultrasonographic, MRI, or [18F]fluorodeoxyglucose PET evaluation of large vessels. Glucocorticoids are the primary therapy for PMR and GCA. Methotrexate may be used in patients at high risk for glucocorticoid adverse effects and patients with frequent relapse or needing protracted therapy. Other therapeutic approaches including interleukin 6 antagonists are under evaluation.",
keywords = "Giant cell arteritis, Glucocorticoids, Polymyalgia rheumatica, Treatment",
author = "Matteson, {Eric Lawrence} and Frank Buttgereit and Christian Dejaco and Bhaskar Dasgupta",
year = "2016",
doi = "10.1016/j.rdc.2015.08.009",
language = "English (US)",
volume = "42",
pages = "75--90",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis

AU - Matteson, Eric Lawrence

AU - Buttgereit, Frank

AU - Dejaco, Christian

AU - Dasgupta, Bhaskar

PY - 2016

Y1 - 2016

N2 - Diagnosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is based on typical clinical, histologic, and laboratory features. Ultrasonographic imaging in PMR with assessment especially of subdeltoid bursitis can aid in diagnosis and in following response to treatment. In GCA, diagnosis and disease activity are supported with ultrasonographic, MRI, or [18F]fluorodeoxyglucose PET evaluation of large vessels. Glucocorticoids are the primary therapy for PMR and GCA. Methotrexate may be used in patients at high risk for glucocorticoid adverse effects and patients with frequent relapse or needing protracted therapy. Other therapeutic approaches including interleukin 6 antagonists are under evaluation.

AB - Diagnosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is based on typical clinical, histologic, and laboratory features. Ultrasonographic imaging in PMR with assessment especially of subdeltoid bursitis can aid in diagnosis and in following response to treatment. In GCA, diagnosis and disease activity are supported with ultrasonographic, MRI, or [18F]fluorodeoxyglucose PET evaluation of large vessels. Glucocorticoids are the primary therapy for PMR and GCA. Methotrexate may be used in patients at high risk for glucocorticoid adverse effects and patients with frequent relapse or needing protracted therapy. Other therapeutic approaches including interleukin 6 antagonists are under evaluation.

KW - Giant cell arteritis

KW - Glucocorticoids

KW - Polymyalgia rheumatica

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84961248126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961248126&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2015.08.009

DO - 10.1016/j.rdc.2015.08.009

M3 - Article

C2 - 26611552

AN - SCOPUS:84961248126

VL - 42

SP - 75

EP - 90

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 1

ER -